Huabei Pharmaceutical Group And DSM Agree On Joint Ventures
This article was originally published in PharmAsia News
Huabei Pharmaceutical Group and DSM drafted 19 initial agreements for joint projects last November, including increasing the former's capital, joint ventures on nutrition products, assets transfer and technology permission. Although the final agreements have not been signed, the draft raises the likelihood of the collaboration to proceed. Huabei Pharmaceutical has identified seven priorities for 2009, and will quickly finalize the joint ventures and introduce funds, technology and management. Analysts observe that the firm will extend its raw Vitamin C materials to downstream formulation business as well as transfer DSM's "green enzyme techniques" to produce penicillin, while DSM is poised to get a slice of China's huge market from the partnership. (Click here for more - Chinese Language)
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.